Strata Critical Medical, Inc. SRTA NASDAQ · Healthcare · United States
$4.56 -5.59% -$0.27
Summary
37 / 100 · Bulios Score
What speaks for it
- It holds more cash than debt: $35.1M against $3.62M.
- Revenue grew by 10% a year over the last 3 years.
What to watch
- The company made a loss over the last 12 months.
- The share price is above the Bulios Fair Price.
- It missed profit estimates 5 times in the last 7 quarters.
- It passes only 3 of the 9 points of the Piotroski financial health test.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBy our assumptions the business is worth less than its shares cost today.
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
The company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
SlowlyRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 53% a year over 5 years. Over the last 3 years it grew by 10% a year.
Growth in detailDoes it make money?
PoorlyOver the last 12 months it made a loss of $24.8M.
Profitability in detailIs it financially healthy?
YesRepaying all its debt would take 11.3 years of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 6
- Hold 0
- Sell 0
Today's price within the analysts' price targets
The average target of $7.25 is 59% above today's price. 100% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Logistics 90%
- Clinical 10%
By region
- UNITED STATES 88%
- Non-US 12%
Logistics brings in 90% of revenue.
Segments in detail